PFO
KRON

Pathstone Family Office’s Kronos Bio KRON Stock Holding History

Pathstone Family Office’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$15.6K Hold
12,034
– – ﹤0.01% 1651
2023
Q2 		$20.7K Hold
12,034
– – ﹤0.01% 1232
2023
Q1 		$17.6K Sell
12,034
-12,034
-50% -$23.1K ﹤0.01% 1180
2022
Q4 		$401K Hold
24,068
– – ﹤0.01% 1190
2022
Q3 		$80.3K Buy
24,068
+12,034
+100% +$54.3K ﹤0.01% 1426
2022
Q2 		$43.8K Hold
12,034
– – ﹤0.01% 1023
2022
Q1 		$87K Buy
+12,034
New +$103K ﹤0.01% 928
2021
Q1 		– Sell
-50
Closed -$1K – 1026
2020
Q4 		$1K Buy
+50
New +$1.57K ﹤0.01% 1098

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Pathstone Family Office's KRON Position: Q3 2023 in Review

Pathstone Family Office held its Kronos Bio (KRON) position steady in Q3 2023 at 12,034 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1651.

Pathstone Family Office first reported a position in KRON in Q4 2020 and has held it in 8 quarters since. The position peaked at $401K in Q4 2022. 63 funds tracked by Wall St. Rank hold KRON as of Q3 2023.

  • Pathstone Family Office held 12,034 shares of Kronos Bio worth $15.6K as of Q3 2023.
  • Pathstone Family Office left its Kronos Bio share count unchanged in Q3 2023.
  • Kronos Bio made up ﹤0.01% of Pathstone Family Office's portfolio in Q3 2023, its #1651 holding.
  • Pathstone Family Office first reported a position in Kronos Bio in Q4 2020 and has held it in 8 quarters since.
  • Pathstone Family Office's Kronos Bio position peaked at $401K in Q4 2022.
  • 63 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.